Imutex Limited, formed in 2016, is a joint venture between PepTcell and hVIVO, to accelerate the development of a Broad-Spectrum ‘Universal’ Influenza Vaccine, FLU-v, and a Mosquito-Borne Diseases Vaccine, AGS-v.
The development of the FLU-v Universal Flu Vaccine and the AGS-v Mosquito-Borne Diseases vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.
Imutex is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate development of both vaccines.
Learn more about AGS-v here and FLU-v here.
Background information on Universal and Annual Flu vaccines can be found at www.endfluenza.com